ELVN
Enliven Therapeutics, Inc.
$59.82
+1.53%
2026-08-21
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Key Fundamentals
Forward P/E
-25.63
EPS (TTM)
$-1.65
ROE
-15.3%
Profit Margin
0.0%
Debt/Equity
0.17
Price/Book
4.81
Beta
0.24
Market Cap
$4.31B
Avg Volume (10D)
1.3M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$62.32
60D Low
$33.45
Avg Volume
1.4M
Latest Close
$59.82
Get breakout alerts for ELVN
Sign up for Breakout Scanner to receive daily notifications when ELVN triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Enliven Therapeutics, Inc. (ELVN) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ELVN daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ELVN operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.